FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Phase 1/2 Completed 50 enrolled National Cancer Institute (NCI)

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Timeline

Start: 2005-01
Primary completion: 2008-12
Completion: 2009-03

Publications

Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16. doi: 10.1093/neuonc/nor017. Epub 2011 Mar 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Romidepsin	Peptide	13.3 mg/m2	Intravenous
Subject	Romidepsin	Peptide	17.7 mg/m2	Intravenous

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Summary

Timeline

Publications

Drugs

Indications